Bookmark

Add to MyYahoo RSS

Eisai Co News

News on Eisai Co (Ticker: ESALY) continually updated from thousands of sources around the net.

Thursday Aug 21 | PR-inside.com

New Market Research Report: Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review

Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations.

Comment?

Related Topix: Biotech, Healthcare Industry

Tue Aug 19, 2014

Sys-Con Media

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S.

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. Seeking Indication Expansion as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures Tokyo, Aug 20, 2014 - - Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe for the indication ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Seizures, Health

Mon Aug 18, 2014

Sys-Con Media

Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan

Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor discovered and developed in-house by Eisai.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Marketing

Fri Aug 15, 2014

PR-inside.com

"Eisai Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Published

The company's major products include Aricept for Alzheimer's treatment, Aciphex for acid reflux, Aloxi anti-nausea medication injection, Belviq diet drug, Dacogen for the treatment of myelodysplastic syndromes, Banzel for adjunctive treatment, Fragmin low molecular weight heparin, Ontak antineoplastic agent, Panretin for the treatment of skin ... (more)

Comment?

Related Topix: Biotech, Medicine, Eisai, Healthcare Industry, Marketing, Panretin, Alitretinoin (generic), Sarcoma, Zonegran, Zonisamide (generic), Health

Wed Aug 06, 2014

Sys-Con Media

Eisai Supports Earthquake Relief Efforts in Yunnan, China

Tokyo, Aug 7, 2014 - - Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, World News, China, Asia,

Wed Jul 30, 2014

Sys-Con Media

EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment

Leading Toward the Submission of Application for Marketing Authorization in Europe Tokyo, July 31, 2014 - - Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency for its in-house developed anticancer agent lenvatinib mesylate in the treatment of ... (more)

Comment?

Related Topix: Biotech, Healthcare Industry, Marketing, Thyroid Cancer, Health

•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••